Ruxolitinib targets DCs: for better or worse?
In this issue of Blood, Heine et al demonstrate the dose-dependent inhibitory effect of ruxolitinib on the generation of dendritic cells (DCs) from monocytes. The drug also inhibited DC activation, tissue migration, and induction of allogeneic or antigen-specific T-cell responses, including in vivo viral clearance.
Mayo Clinic, USA.
Ayalew
A
Tefferi
D000818:Animals; D000938:Antigen-Presenting Cells / Q000187:drug effects*; D003713:Dendritic Cells / Q000187:drug effects*; D006801:Humans; D053612:Janus Kinases / Q000037:antagonists & inhibitors*; D009570:Nitriles; D011720:Pyrazoles / Q000494:pharmacology*; D011743:Pyrimidines; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects*
D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib; D053612:Janus Kinases